Skip to: Content
Skip to: Site Navigation
Skip to: Search
TUESDAY, NOVEMBER 24, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter

NEWS ABOUT: Bristol Myers Squibb

Bristol Myers Squibb stories: 5 news summaries

 Big Pharma Flouts Laws 
 on Off-Label Uses 

Billions in fines don't stop illegal promotion

Nov 9, 09 8:19 AM CST
(Newser) - Back in 2004, a unit of drug giant Pfizer pleaded guilty to marketing a drug, Neurotonin, for unapproved uses, paid $430 million in fines, and promised to clean up its act—which it had no intention of doing. "At the very same time Pfizer was in our office negotiating... More »

MORE ABOUT:
marketing • drug companies • Pfizer • prescription drugs • Eli Lilly • settlement • off label drug use • Bristol Myers Squibb

 Novartis Acquires Plavix Rival 

Novartis acquires worldwide rights from a San Francisco biopharmaceutical firm

Feb 12, 09 8:22 AM CST
(Newser) - Novartis AG will pay a San Francisco biopharmaceutical company $75 million—with the potential for an additional $500 million—for the worldwide rights to an experimental anticlotting drug the Swiss drug firm hopes will rival Plavix, reports the Wall Street Journal. Market leader Plavix rang up $8.22 billion... More »

MORE ABOUT:
pharmaceutical companies • Eli Lilly • Lipitor • prasugrel • Plavix • Bristol Myers Squibb • Novartis AG • Portola Pharmaceuticals • elinogrel

Bristol-Myers Makes Bid for Icahn's ImClone

Offers 29% premium for biotech partner; shares soar

Jul 31, 08 1:21 PM CDT
(Newser) - Already a 17% shareholder, Bristol-Myers Squibb laid down a $4.5 billion offer to buy the  rest of ImClone shares, the Wall Street Journal reports. The $60-a-share offer, sent to ImClone chairman Carl Icahn today, is a 29% premium on yesterday's closing price and makes Bristol the second pharma... More »

MORE ABOUT:
Carl Icahn • mergers and acquisitions • Bristol Myers Squibb • pharmaceutical industry • ImClone

SEC Delves Deeper Into Execs' Pay

Regulator pushes companies to reveal criteria for measuring performance

Jan 29, 08 3:28 PM CST
(Newser) - The SEC wants companies to tell shareholders how they measure an executive’s performance when calculating pay, but companies are balking, reports the Wall Street Journal. Their reticence has prompted the commission to send out a second wave of letters to some of the 350 companies it originally queried... More »

MORE ABOUT:
executive compensation • earnings reports • SEC • Bristol Myers Squibb • share price

Bristol-Myers
to Slash Jobs, Shut Plants

Drugmaker shrinks, says expiring patents will cut profits

Dec 5, 07 6:09 PM CST
(Newser) - Bristol-Myers Squibb said today it will lay off 10% of its work force—totaling 4,300 jobs—and close or sell half its 27 factories in a plan to save $1.5 billion by 2010, the Wall Street Journal reports. The firm also will sell its medical-imaging division and possibly... More »

MORE ABOUT:
pharmaceutical companies • Bristol Myers Squibb • downsizing

5 Stories


from our news partners